Idiopathic thrombocytopenic purpura (ITP), a condition that affects the blood by low platelet count, may be associated the Oxford-AstraZeneca COVID vaccine in rare cases.
E-Mail
A condition that affects the blood, known as idiopathic thrombocytopenic purpura (ITP), may be associated the Oxford-AstraZeneca vaccine in rare cases, research suggests.
The very small increased risk of the condition - which is characterised by low platelet counts - is estimated to be 11 per million doses, similar to figures seen in vaccines for flu and MMR.
A low number of platelets - blood cells that help prevent blood loss when vessels are damaged - can result in no symptoms or can lead to an increased risk of bleeding or, in some cases, clotting.
Researchers say that the increased chance of developing ITP after receiving the vaccine remains smaller than the risk of developing it because of Covid-19 and should not deter the roll out of the vaccine programme.
141 views
Three industrial consortia that will link together to deliver deep reductions in industrial emissions on the east coast of England have been awarded funding as part of the Industrial Decarbonisation Challenge under the UK Research and Innovation’s Industrial Strategy Challenge Fund (ISCF).
The three bids amount to £229 million in private and public funding, with industry contributing two-thirds of the total, and will support the next stage in development of the three projects.
Across the various clean energy topics we track and talk about, a common theme has been emerging recently - a focus on the importance of particular geographic clusters.
Lightsource BP to develop solar and green hydrogen for £20m South Wales Industrial Cluster solarpowerportal.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from solarpowerportal.co.uk Daily Mail and Mail on Sunday newspapers.
These updates are republished press releases and communications from members of the Science|Business Network
Innovate UK: UK registered businesses can apply for a share of up to £46.8M for quantum projects
UK registered businesses can apply for a share of up to £46.8 million for collaborative research and development or technology projects in quantum.
The aim of this competition is to advance the commercialisation of quantum technologies in the UK and increase private sector investment.
The competition is being funded through UK Research and Innovation’s Industrial Strategy Challenge Fund for commercialising quantum technologies.
This is a £153 million fund, supported by a significant investment from industry, to remove technical barriers and deliver new products and services based on advances in quantum technology.